92 results about "Cerebrum" patented technology

The invention discloses a method, device and equipment for generating a head model, a storage medium and a program product. The method is characterized by comprising the following steps of: receiving and verifying original three-dimensional T1 weighted image data and an original three-dimensional grid model; performing tissue segmentation based on the verified three-dimensional T1 weighted image data and the original three-dimensional T1 weighted image data to obtain a cerebral grey matter mask, a cerebral white matter mask, a scalp mask and a skull mask; performing topological structure repair on the brain grey matter mask and the brain white matter mask to obtain a brain mask; respectively converting the scalp mask, the skull mask and the brain mask into a scalp mesh model, a skull mesh model and a brain mesh model; calculating and applying a spatial transformation matrix from the verified three-dimensional grid model to the scalp grid model, and performing spatial registration and fusion on the scalp grid model, the skull grid model and the brain grid model to obtain a head model; the method has the advantages that the efficiency, precision and robustness of head model generation are effectively improved, and the method has good cross-platform deployment capability.

The disclosure relates to devices and methods for applying a magnetic field on a body of a patient. The time-varying magnetic field may applied to a brain of the patient. The disclosure provides a method of finding the position suitable for application of the magnetic field to the brain. The devices and methods of the disclosure may be suitable for reducing of food craving.

The invention belongs to the technical field of nutritious food, and particularly discloses a composition for promoting brain development and application thereof. The composition for promoting brain development provided by the invention comprises bifidobacterium longum subsp. Infantis i18 and sn-2 site docosahexaenoic acid. According to the composition provided by the invention, all the components have a synergistic effect, so that the accumulation of DHA in cerebral cortex and hippocampus can be remarkably improved, and the purpose of promoting brain development is achieved. The composition is suitable for health food, formula milk powder or fermented milk and other products for improving cognition and promoting brain development.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

Disclosed is a marking composition comprising a marker and a hydrogel. Disclosed is a process of forming a marking composition comprising mixing a marker and a hydrogel. Disclosed is an article comprising a marker, a hydrogel, and an implement. Disclosed is a kit comprising a marker, a hydrogel, and an implement, wherein the marker and hydrogel are combined. Disclosed is a method for marking a portion of the brain in a mammal comprising: (a) removing a portion of a mammal's skull to expose a portion of the brain matter; and (b) contacting the exposed portion of the brain with a marking composition. Disclosed is a method for recording electrical activity in a brain, comprising: (a) removing a portion of the skull, thereby exposing a portion of a brain; (b) inserting an electrode into the brain; and (c) recording electrical activity via the electrode, wherein the electrode is at least partially coated with a marking composition.

A method for determination of an indicator representative of a change in the brain caused by a demyelinating disease, the method including, for each region of interest of the brain, determining a regional coefficient of one of the following diffusion coefficients: the radial diffusion, the axial diffusion, the mean diffusion, the anisotropy fraction, or a combination of several of these coefficients, the regional coefficients being determined from a diffusion MRI image; determining a number of changed regions, for which a condition relating to the value of the regional diffusion coefficient of each region is satisfied; and determining the indicator in accordance with the number of changed regions.

Active medicine materials of the traditional Chinese medicine composition comprise saffron, nutmeg, clove, sandalwood and apium graveolens according to the weight ratio of 100: n1-n2: n3-n4: n5-n6: n7-n8, n1, n2, n3, n4, n5, n6, n7 and n8 are all natural numbers, n1 is larger than or equal to 100 and smaller than or equal to 300, n3 is larger than or equal to 100 and smaller than or equal to 400, n5 is larger than or equal to 200 and smaller than or equal to 800, n7 is larger than or equal to 50 and smaller than or equal to 400, and n7 is larger than or equal to 400. The composition can prevent, treat, slow down or control stroke-heart syndrome, middle cerebral artery embolism and myocardial injury of subjects, and has popularization prospects.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and / or one or more active agents are administered to a subject in need thereof to reduce or inhibit the activity of CeA PKC-δ neurons and ovBNST PKC-δ neurons in the brain of the subject. Preferably, the disclosed methods are effective to increase or excite the activity of the brain regions downstream of CeA PKC-δ neurons and ovBNST PKC-δ neurons including medial part of CeA and ventral lateral part of BNST.

The invention discloses a lipophilic modified nucleic acid medicine composition and application thereof, the lipophilic modification is saturated or unsaturated C4-C30 alkyl, the composition comprises an absorption enhancer, and the method is that the lipophilic modified nucleic acid medicine is delivered to the brain through the nasal mucosa. Nucleic acid drugs are transmitted into the olfactory bulb region through a neural pathway, namely, cross-olfactory mucosa, bypass BBB and directly enter the brain, the drug concentration content of the olfactory bulb is far higher than that of other tissues of the brain, and the tissues except the olfactory bulb are uniformly distributed, so that the olfactory bulb can be used as a drug reservoir and gradually and slowly spread to the other tissues of the brain; the long-time drug effect can be maintained by one-time drug administration, so that the drug administration frequency can be reduced. Compared with intrathecal injection, by adopting the composition disclosed by the invention for nasal administration and using 1 / 2 of intrathecal administration dosage, the same intrathecal steady-state distribution as intrathecal distribution can be achieved, so that the method disclosed by the invention is safer, noninvasive and efficient.

The invention discloses a dummy head injury testing device and method for an impact test, the testing device comprises a head assembly, the head assembly comprises a skull, brain tissue, head skin and a sensing device, eye sockets are arranged on the skull, and bionic eyeballs are arranged at the eye sockets; the brain tissue comprises bionic brain tissue and bionic cerebrospinal fluid; the head skin comprises a head skin body and flexible sensing skin arranged on the outer surface of the head skin body, the flexible sensing skin comprises a flexible substrate layer, wire electrodes arranged on the two end faces of the flexible substrate layer respectively and insulating layers covering the wire electrodes, and a plurality of wire electrodes are arranged on the two end faces at intervals. The wire electrodes on the two end faces are orthogonally arranged to form an array structure, and raw materials of the flexible substrate layer comprise silicone rubber and a conductive material. The testing device is good in biological simulation degree, the testing result is closer to the real situation, multiple sensor configuration schemes are provided, and more head injury data can be obtained.

To provide a gene construct for use in the treatment of a metabolic disorder in a mammal, particularly a human.SOLUTION: A gene construct provided comprising a nucleotide sequence encoding fibroblast growth factor 21 (FGF21) for use in the treatment and / or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS), preferably in the brain, more preferably in the hypothalamus and / or cortex and / or hippocampus and / or cerebellum and / or olfactory bulb, and most preferably in the hypothalamus.SELECTED DRAWING: None

The present application relates to endogenous NMDA receptor subtypes in brain tissue and their assembly and structure. The present application provides a method for evaluating the function of endogenous NMDA receptors in brain tissue (cortex and hippocampus), comprising obtaining data on the structure and / or quantity of endogenous NMDA receptors (NMDAR) in the brain tissue, wherein the NMDA receptor comprises a GluN1-N2A-N2B triheteromer; and comparing the structure and / or quantity of the GluN1-N2A-N2B triheteromer with a reference structure and / or quantity reference value, thereby giving an evaluation result of the function of endogenous NMDA receptors in brain tissue. The present application also provides a device for performing the evaluation and a method for drug screening based on changes in the structure and / or quantity of specific NMDA receptors.

The invention relates to a multi-mode eye-brain collaborative maintenance intelligent device, and belongs to the technical field of eye-brain nursing equipment.The device is provided with an impression stimulation module, the impression stimulation module stimulates mild energy of an impression acupoint, the mild energy can be directly conducted to a paranasal sinus olfactory bulb in the deep part of a nasal cavity, the area is the starting end of paranasal sinus nerves, the paranasal sinus nerves are branches of cranial nerves, and therefore the paranasal sinus acupoint can be stimulated; the neural pathway directly extends to brain hippocampus, brain marginal tissue, pituitary gland and other core structures related to neuronutrition and brain metabolism; after stimulation, the paranasal sinus olfactory bulb and paranasal sinus nerves are activated to form a neural pathway for targeted delivery of the atomized liquid, so that the atomized particles of the brain care liquid are adsorbed on the surface of the paranasal sinus olfactory bulb and permeate into the brain along the activated neural pathway, and meanwhile, the permeability of the blood brain barrier is improved, so that the delivery resistance of the atomized liquid to related functional areas of the brain is further reduced, and the targeted delivery of the atomized liquid is realized. Precise nutrition for cranial nerves is achieved, and the problem that brain maintenance is invalid due to the fact that conventional nasal cavity atomized liquid enters the lung is thoroughly solved.

Methods and systems for programming stimulation parameters for assisting deep brain stimulation (DBS) in experimental patients are described. A cumulative database includes data from multiple historical adaptation / programming sessions. The data may include various sets of stimulation parameters tried for patients in the database; data relating to the position of electrode leads relative to the anatomical features of the patient's brain, such as alignment with the subthalamic nucleus (STN); scores indicating the therapeutic effectiveness of the stimulation parameters; and data relating to stimulation field models (SFM) of the various sets of stimulation parameters. This database can be used to predict stimulation parameter sets that may be therapeutically effective for experimental patients.

The Great Cerebral Vein, or Vein of Galen is comprised of a unique structure having a location which both implicates it in various clinical conditions, and can be treated by systems which, for example, go around corners of the Transverse and Straight sinuses for minimally invasive therapy embedded in the Vein of Galen the present inventions constitute progress in science and the useful arts worthy of protection as US Letters patent as novel.

A system for the real-time detection of cerebral ischemic events using multichannel near-infrared spectroscopy, comprising: a head-attachable structural assembly made of a flexible or semi-rigid biocompatible substrate configured to conform to the skull surface of a subject; a plurality of near-infrared light-emitting units embedded in the structure and arranged in a spatially distributed configuration over predefined areas corresponding to brain regions; a plurality of photodetector units arranged at predetermined distances from the respective light-emitting units to define a plurality of measurement channels, each measurement channel configured to receive diffusely reflected near-infrared light from the underlying brain tissue;a signal acquisition unit electrically coupled to the photodetector units and configured to convert received optical signals into corresponding electrical signals, and additionally amplifying, filtering, and digitizing them; a processing unit operationally coupled to the signal acquisition unit and configured to calculate fluctuations in cerebral oxygenation based on the digitized signals and to identify patterns indicative of cerebral ischemic events in real time; and a communication unit configured to transmit processed data and event notifications to an external system.

The utility model relates to the technical field of fixing devices, in particular to an integrated fixing device for manufacturing rodent pathological sections, which comprises a fixing device shell and a fixing device cover plate which are rotatably connected. The fixing device comprises a fixing device shell, a plurality of brain cutting clamping grooves are formed in the periphery of the fixing device shell, brain clamping grooves are formed in the bottom of the fixing device shell, the brain clamping grooves comprise a cerebellum fixing groove, a brain fixing groove and an olfactory bulb fixing groove, and the cerebellum fixing groove, the brain fixing groove and the olfactory bulb fixing groove are integrated. The closed fixing groove can be adopted, formalin volatilization is reduced, the brain tissue fixing function and the material taking function are integrated, and the operation process is simplified.

The brain is slightly off-centered within the skull. In addition, current patient immobilization implements do not provide sufficient position (posture) reproducibility, and aligning a device in order to accurately irradiate a treatment target site in the brain takes a long time.　A subject positioning method according to the present invention includes: a step for obtaining a treatment planning image of a subject immobilized relative to a reference plane in order to make a treatment plan for the subject; a step for obtaining a pre-treatment image of the subject immobilized relative to the reference plane immediately prior to treatment of the subject; a step for determining a posture correction value with which the cerebral sulci in the treatment planning image and the cerebral sulci in the pre-treatment image can be made to overlap; and a step for correcting the posture of the subject during treatment on the basis of the posture correction value. In the subject positioning method, the cerebral sulci in the treatment planning image and the pre-treatment image are adjusted to coincide with each other, whereby radiation can be accurately applied to the treatment target site.

Methods and systems are described for stimulation parameter programming to assist in deep brain stimulation (DBS) of a subject patient. The cumulative database includes data from a plurality of historical adaptation / programming sessions. The data may include various sets of stimulation parameters attempted for the patient in a database; data relating to the position of the electrode lead relative to an anatomical feature of the patient's brain, e.g., alignment with respect to its subthalamic nucleus (STN); a score of the stimulation parameter indicative of therapeutic effectiveness of the stimulation parameter and / or causing a side effect in the patient; and data relating to a stimulation field model (SFM) of the various sets of stimulation parameters. The database may be used to predict sets of stimulation parameters that may be effective or cause side effects to the treatment of the subject patient.

Some methods comprise, for each of one or more lesions of a patients brain, from data taken at first and second times, determining two or more lesion characteristics including a lesion's volume change and whether the lesion moved toward a center of the brain. Some methods comprise, for each lesion, determining whether one or more criteria are satisfied, including a volume-and-displacement-based criterion that is satisfied when the change in the volume of the lesion is less than zero and the lesion moved toward the brain's center or the change in the volume of the lesion is greater than zero and the lesion did not move toward the brain's center. Some methods comprise characterizing whether the patient has multiple sclerosis and / or the progression, regression, or stability of multiple sclerosis based at least in part on the assessment of the one or more criteria for each of the lesion(s).

The present invention discloses a composition for improving cognitive function using a single or complex extract of Acanthopanax koreanum, Astragalus membranaceus, and / or Momordica charantia. The composition increases, in an in-vitro efficacy test, the cell viability of SH-SY5Y cells, which are human-derived neuroblastomas treated with scopolamine that is an oxidative stress-inducing drug, increases the expression of an apoptosis inhibition-related biomarker (Bcl-2), an autophagy-enhancing biomarker (Beclin-1), and an acetylcholine biosynthesis-related enzyme (ChAT), which are neurotransmitters, also increases the expression of the antioxidant-related biomarker HO-1, and increases the inactivation of GSK-3β, which is a therapeutic target for Alzheimer's disease, and furthermore, even in an in-vivo efficacy test, increases the expression of Bcl-2, Beclin-1, ChAT, and HO-1 in the hippocampus and cerebrum of an animal model with reduced cognitive function and memory induced by administration of scopolamine, and inhibits the expression of iNOS, which is an enzyme involved in NO biosynthesis that induces tissue damage.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Specifically, the targeting peptide is a component of a modified, sequence-specified adeno-associated virus (AAV) capsid protein further wherein the brain substructure may be the globus pallidus, putamen, internal capsule, caudate, claustrum, substantial nigra, motor cortex, insula,.temporal cortex, thalamus, hippocampus, subiculum, and deep cerebellar nuclei.

The present invention relates to the field of data anomaly detection technology, specifically an anomaly detection device based on the cerebral neocortex mechanism. The anomaly detection device comprises a multi-core controller, a cortical column component, and a neuron component, and is connected to a PC motherboard via a PCIe interface. The present invention is a computer accessory that uses a PCIe interface to connect to a computer and access various data through a network to perform anomaly detection. This device is a general anomaly detection device that can be used in equipment operation and maintenance, alarms, and other application scenarios.

A portable device for detecting a large vessel occlusion in a patient's brain by transmitting a signal into both sides of the brain and receiving the reflections of the transmitted signals to capture a single reflection data point of the characteristics of the blood vessels and brain tissue on both sides of the brain. Using the captured single reflection data point values to perform a comparative analysis between the right and left side of the brain, and based on this analysis, assessing whether the patient is experiencing a large vessel occlusion. If so, the device generates an alert.

The invention discloses an improved and simplified modeling method of a rat middle cerebral artery embolism ischemia model and an auxiliary precise thrombus pushing device.According to the modeling method, standardized thrombus embolism is prepared through an in-vitro step, and the modeling method comprises the steps that blood is incubated in a PE-50 catheter at the specific temperature for the specific time to form initial thrombus; the diameter is accurately controlled to be smaller than 0.14 mm through reciprocating push-pull and negative pressure folding suction of a PE-10 catheter; then, loading the emboli by using a normalized vascular catheter with a 20mm pre-mark; during modeling, the catheter is inserted to a preset depth through an external carotid artery, and the thrombus is pushed into a target blood vessel at a constant speed of 10-20 [mu] L / min by means of an auxiliary precise thrombus pushing device. The core problems of poor thrombus quality and low model stability and repeatability of a traditional method are effectively solved by optimizing the whole process of thrombus preparation, catheter specification, pushing rate and verification standard in combination with a special device, the success rate of the model can reach 90% or above, and an efficient and reliable experimental tool is provided for cerebral apoplexy research.

Conventionally, the arterial input function is determined by administering a contrast agent and measuring the responsive magnetic signal in a reference voxel located in a large artery such as the middle cerebral artery. By instead measuring the signal in a voxel of the choroid plexus, a more accurate profile for the arterial input function may be obtained. The metabolic activity in the choroid plexus is negligible, which provides greater certainty for signal sampling.